TCM
BOLT icon

Tang Capital Management’s Bolt Biotherapeutics BOLT Stock Holding History

Tang Capital Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-66,879
Closed -$356K – 95
2025
Q3 		$356K Sell
66,879
-100,000
-60% -$554K 0.01% 187
2025
Q2 		$963K Sell
166,879
-23,760
-12% -$157K 0.05% 156
2025
Q1 		$1.53M Hold
190,639
– – 0.08% 135
2024
Q4 		$2.04M Hold
190,639
– – 0.14% 106
2024
Q3 		$2.47M Hold
190,639
– – 0.18% 91
2024
Q2 		$2.86M Buy
190,639
+19,639
+11% +$387K 0.29% 70
2024
Q1 		$4.79M Sell
171,000
-11,612
-6% -$269K 0.5% 62
2023
Q4 		$4.09M Buy
182,612
+4,760
+3% +$92.7K 0.38% 64
2023
Q3 		$3.7M Buy
177,852
+11,162
+7% +$273K 0.52% 51
2023
Q2 		$4.27M Buy
166,690
+85,312
+105% +$2.71M 0.63% 45
2023
Q1 		$2.26M Buy
81,378
+61,378
+307% +$1.8M 0.34% 64
2022
Q4 		$520K Buy
20,000
+10,000
+100% +$274K 0.08% 75
2022
Q3 		$296K Hold
10,000
– – 0.04% 91
2022
Q2 		$408K Buy
+10,000
New +$388K 0.06% 67

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tang Capital Management's BOLT Position: Q4 2025 in Review

Tang Capital Management sold out of Bolt Biotherapeutics (BOLT) in Q4 2025, closing a stake of 66,879 shares — an estimated $356K sold.

Tang Capital Management first reported a position in BOLT in Q2 2022 and held it in 14 quarters. The position peaked at $4.79M in Q1 2024. 21 funds tracked by Wall St. Rank hold BOLT as of Q4 2025.

  • Tang Capital Management reported no remaining Bolt Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Tang Capital Management sold 66,879 Bolt Biotherapeutics shares in Q4 2025, an estimated $356K.
  • Tang Capital Management first reported a position in Bolt Biotherapeutics in Q2 2022 and held it in 14 quarters.
  • Tang Capital Management's Bolt Biotherapeutics position peaked at $4.79M in Q1 2024.
  • 21 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.